Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

In8Bio, Inc.

NASDAQ: INAB · Life Sciences · 2 alerts · CIK 1740279

Share price
$0.8160Close, Nov 16
Market cap
$8.82M
Shares outstanding
10.81MLatest SEC cover page
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All In8Bio, Inc. filings on SEC EDGAR ↗

4:18 PM ET 10-Q
Financial Results

In8Bio Q3 2026 Results: Net Loss of $4.59M, Loss Widens

IN8BIO, INC. reported a net loss of $14.5 million for the nine months ended September 30, 2026, which was consistent with the prior year period. The company's cash position decreased significantly from $27.1 million at the end of 2025 to $14.0 million as of September 30, 2026, primarily due to $12.6 million used in operating activities.

Key figure
Net loss $4.59M
4:15 PM ET 8-K
Financial Results

In8Bio Financial Results

IN8bio reported financial results for the third quarter of 2026, highlighting the appointment of Dr. Oxana Polyakova as SVP of R&D and progress in its gamma-delta T cell engager platform. The company remains on track to report initial in vivo preclinical data for its INB-619 program by the end of 2026.

Term
Q3 2026

“This quarter we continued to build upon our deep expertise in γδ T cells, officially welcoming Dr. Polyakova to the team and making progress with our proprietary TCE platform. It’s also exciting to see the external recognition that the unique properties of γδ T cells and their tissue-specific distribution, “may offer a unique opportunity to eliminate pathogenic cells more precisely and deeply in target organs” as stated in the Nature Reviews article. We believe this platform has the potential to enable a new class of therapeutics for autoimmune diseases and oncology, and we are excited to present our initial animal data by year-end.”

William Ho, CEO and co-founder of IN8bio

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.